Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering
July 19, 2011 11:35 ET
|
Ventrus Biosciences
NEW YORK, July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced...
Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock
July 14, 2011 09:18 ET
|
Ventrus Biosciences
NEW YORK, July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the...
Ventrus Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND
June 22, 2011 08:00 ET
|
Ventrus Biosciences
NEW YORK, June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special...
Ventrus Receives Notice of Allowance for U.S. Patent for VEN 307
May 31, 2011 16:00 ET
|
Ventrus Biosciences
NEW YORK, May 31, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. announced today that the claims in its currently pending U.S. Patent Application No. 09/355,928, titled "TOPICAL PHARMACEUTICAL...
Ventrus Adds Third Treatment Arm of Shorter Treatment Duration to Its Phase III Study of Iferanserin in Hemorrhoids
May 02, 2011 16:16 ET
|
Ventrus Biosciences
NEW YORK, May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309),...
Ventrus Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study
March 18, 2011 16:02 ET
|
Ventrus Biosciences
NEW YORK, March 18, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) has filed a revised protocol with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment...
Ventrus Hires inVentiv Clinical Solutions and Almac Group for Its Phase III Pivotal Trial in the Treatment of Hemorrhoids With Iferanserin Ointment
March 03, 2011 14:24 ET
|
Ventrus Biosciences
NEW YORK, March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
Ventrus to Present at 2011 BIO CEO & Investor Conference
February 07, 2011 16:24 ET
|
Ventrus Biosciences
NEW YORK, Feb. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that...
Ventrus Completes Clinical Development Staffing
February 01, 2011 14:57 ET
|
Ventrus Biosciences
NEW YORK, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the...
Underwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering
January 07, 2011 12:11 ET
|
Ventrus Biosciences
NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today...